Atossa advances (Z)-endoxifen regulatory path; Q3 op-ex $9.3M

ATOSSA THERAPEUTICS, INC.

FDA Type C meeting set Nov 17 to discuss accelerated NDA path for (Z)-endoxifen in breast cancer risk reduction; written comments received.
Appointed Janet R. Rea as SVP R&D and Mark Daniel as CFO to lead commercialization readiness.
Selected PSI as CRO for planned Phase 2 mBC dose-ranging study; IND filing targeted Q4 2025, topline data in 2026.
Q3 operating expenses $9.3M (up from $6.4M); interest income $0.6M; net loss not separately disclosed.
New Israel patent issued; two US patents under post-grant challenges; majority of IP portfolio unaffected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.